{
    "nctId": "NCT00631852",
    "briefTitle": "A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer",
    "officialTitle": "A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 16,
    "primaryOutcomeMeasure": "Adiponectin",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with cytologically confirmed breast cancer with biopsy showing invasive or non-invasive (DCIS) at least 1.0 cm greatest diameter on imaging\n* Surgical patients undergoing lumpectomy, subtotal or total mastectomy\n* 18 years of age or greater\n* female\n* available tissue blocks from diagnostic biopsy\n* negative pregnancy test, medical history of surgical sterilization, or 1 year post menopausal\n* must be willing to forego surgery for minimum of 5 days\n* ability and willingness to sign written consent\n* if hypertensive, on stable dose of medication at least 30 days\n* if diabetic, well controlled (HbA1C \\< 8.5 within past 60 days or documented FPG \\< 140 mg/dl for 3 consecutive days\n* ECOG status \\< 2 or Karnofsky of 60% or greater\n\nExclusion Criteria:\n\n* previous or current malignancy, excluding non-melanomic skin cancer\n* evidence of distant metastatic disease\n* history of chemotherapy, biologic or radiotherapy with 6 months of biopsy\n* usage of herbal supplements or alternative medications not approved by the FDA within 1 week of starting study drug. LEAG or related ginseng products, and combination products containing ginseng, should be discontinued within 6 weeks of starting study drug\n* history of allergic reactions attributed to compounds of similar chemical or biologic composition to LEAG\n* history of chronic inflammatory process, including, but not limited to, rheumatoid arthritis and lupus. This includes patients on concurrent systemic steroids or anti-inflammatory medications\n* active bleeding or a pathological condition that carries a high risk of bleeding\n* any swallowing dysfunction\n* uncontrolled intercurrent illness\n* poorly controlled diabetes (control indicated with HbA1c \\< 8.5 within past 60 days or documented fasting blood glucose \\< 140 mg/dl for three consecutive days)\n* known diabetics who have experienced episodes of symptomatic hypoglycemia in the last 6 months are also considered poorly controlled and will be excluded from study participation.\n* uncontrolled hypertension (SBP \\> 140 mmHg or DBP \\> 90 mmHG)\n* pregnant or breast feeding women Women must be willing to use birth control throughout study duration.\n* current investigational medications or treatment with an investigational agent within 6 weeks prior to biopsy\n* current coumadin therapy or who have been treated with coumadin within the 2 weeks prior to biopsy\n* current monoamine oxidase inhibitors treatment",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}